Background/Aims: IL-35, a powerful suppressor of inflammation and autoimmunity, is primarily secreted by regulatory T cells (Tregs) and can, in turn, promote Treg differentiation. However, the precise effect of IL-35 on dendritic cells (DCs) remains to be clarified. Methods: In this study, we investigated the expression of IL-35 in DCs after stimulation with LPS utilizing enzyme linked immunosorbent assay(ELISA), quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR) and western blotting, and the influence of IL-35 on the maturation and function of DCs by mixed lymphocyte reaction assay and flow cytometry. We further examined the regulation of IL-35 in DCs by the microRNA let-7i (let-7i) via transfected with let-7i mimic, inhibitor or suppressor of cytokine signalling 1 (SOCS1) siRNA. IL-35-overexpressing DCs were transfused into BALB/c recipients with C57BL/6 heart transplantations to verify the role of immune tolerance in transplantation. Results: The results showed that IL-35 expression was significantly up-regulated following lipopolysaccharide (LPS)-induced DC maturation. Overexpression of IL-35 suppressed DC maturation, promoted the secretion of anti-inflammatory cytokines, and subsequently affected the balance between Treg and Th17 cells. IL-35 expression in DCs was regulated by let-7i, which targets SOCS1. 
Treatment with recombinant IL-35/Ebi3 or IL-35-neutralising antibodies and transfection with microRNA let-7i mimic, let-7i inhibitor, or SOCS1 siRNA
ImDCs were generated and treated with Ebi3 mouse recombinant protein (10 ng/ml; Rockland, Limerick, PA, USA) or anti-mouse IL-35 monoclonal antibody (10 ng/ml; Rockland, Limerick, PA, USA) for neutralisation on Day 6 for 24 h. Some imDCs were transfected with microRNA let-7i mimic or inhibitor (60 nmol/l; GenePharma, Shanghai, CN) by Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) for 24 h on Day 6. For all transfection protocols, a control group was transfected with a mimic negative control (NC-mimic) or an inhibitor negative control (NC-inhibitor). The sequences were as follows: microRNA let-7i mimic, sense, 5'-UGAGGUAGUAGUUUGUGCUGUU-3', antisense, 5'-CAGCACAAACUACUACCUCAUU-3'; microRNA let-7i mimic negative control, sense, 5'-UUCUCCGAACGUGUCACGUTT-3', antisense, 5'-ACGUGACACGUUCGGAGAATT-3'; microRNA let-7i inhibitor, 5'-AACAGCACAAACUACUACCUCA-3'; microRNA let-7i inhibitor negative control, 5'-CAGUACUUUUGUGUAGUACAA-3'. ImDCs were also transfected with SOCS1 short interfering (si)RNA (60 nmol/l; GenePharma, Shanghai, CN) using Lipofectamine 2000 for 24 h on Day 6. After washing, the cells were cultured for 24 h in the presence of LPS (200 ng/ml) and then collected for other experiments.
Mixed lymphocyte reaction assay
Splenocytes were obtained from male BALB/c mice, and CD3 + T cells were isolated from the splenocytes by magnetic cell separation using anti-CD3 microbeads (Miltenyi Biotech GmBH, Bergisch Gladbach, Germany). To analyse the effect of IL-35/Ebi3-treated DCs or IL-35-neutralising antibody-treated DCs on T cell proliferation, BALB/c mice DCs (1.0×10 5 /ml) were treated with mitomycin C (10 μg/ml, SigmaAldrich, St. Louis, MO, USA) for 4 h and then co-cultured with BALB/c CD3 + T cells (1.0×10 6 /ml) in a 96-well plate for 4 days. These co-cultures were incubated with 10 mM BrdU (Biotrak 2; Amersham, Little Chalfont, UK) for 24 h, and BrdU incorporation by proliferating T cells was quantified using a BrdU enzymelinked immunosorbent assay (ELISA). To analyse the T cell population, BALB/c DCs were pretreated with mitomycin C (10 μg/ml, Sigma-Aldrich, St. Louis, MO, USA) for 4 h and then co-cultured with BALB/c CD3 + T cells at a DC/T cell ratio of 1:10. Subsequently, CD4 + T cells were isolated from the co-cultured MLR cells by magnetic cell separation using anti-CD4 microbeads (Miltenyi Biotech GmBH, Bergisch Gladbach, Germany) for further flow cytology analysis. Quantitative RT-PCR Total RNA was isolated from different groups of DCs using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the protocol recommended by the manufacturer. Reverse-transcription reactions were incubated for 60 min at 37°C and 5 min at 85°C. qRT-PCR was performed according to the TaqMan realtime PCR assay kit (GenePharma, Shanghai, CN) protocol in a total volume of 20 μl using an CFX manager Real-Time System (Bio-Rad Laboratories, Hercules, California). PCR reaction mixtures contained the following components: 10 μl of Universal Master Mix, primer pairs at 10 μM, probe at 10 μM, 1 U of rTaq DNA polymerase and 10 ng of cDNA template. The PCR protocol consisted of 40 cycles of 3 min at 95°C, 12 s at 95°C, and 40 s at 62°C. Quantification of relative mRNA levels of the target genes was performed based on the 2 −ΔΔCt method described by Livak and Schmittgen [27] . The primers used for the real-time PCR reactions are shown in Table 1 . Each sample was measured in triplicate.
Evaluation of cytokine production
To measure cytokine release by DCs, supernatants were collected from cultures after stimulation with LPS, IFN-γ, IL-1β, or TNF-α for 24 h. An IL-35 heterodimer ELISA kit (CUSABIO, Wuhan, CN) was used to detect the concentrations in the supernatants according to the manufacturer's instructions. Some supernatants were obtained from DCs after treatment with IL-35/Ebi3 or IL-35-neutralising antibody or after transfection with microRNA let-7i mimic, inhibitor, or RNA of si-SOCS1 and LPS stimulation for 24 h. Then, we assessed the secreted levels of IL-4, IL-10, IL-12, IL-23, IL-27, TGF-β and IFN-γ (Abcam, Cambridge, UK). In several experiments, the levels of IL-2, IFN-γ, IL-4, and IL-10 (Abcam, Cambridge, UK) were also determined in plasma from BALB/c recipient mice 14 days after transplantation. All assays were performed in triplicate.
Flow cytometry DC purity and phenotype were analysed based on the surface expression of specific markers using flow cytometry. CD11c + DCs were selected by magnetic cell separation and incubated with 0.5 µg of fluorochrome-conjugated PE-CD80, PE-CD86 and PE-MHC-II (eBioscience, San Diego, CA, USA) for 30 min at 37°C. For each staining protocol, the appropriate isotype-matched control was included. The stained cells were assayed using a BD FACSCanto II flow cytometer. To analyse CD4 + CD25 +
Foxp3
+ T cells, cells from MLRs or splenocytes from recipients were transfused with phosphate-buffered saline (PBS), mDCs or IL-35/Ebi3-mDCs 14 days after transplantation. Subsequently, the cells were incubated with 0.5 µg of fluorochromeconjugated CD4-FITC or CD4-PerCP-Cy5.5 and CD25-APC (eBioscience, San Diego, CA, USA) monoclonal antibodies (mAb) for 30 min at 37°C and then fixed and permeabilised in 100 µL of eBioscience Perm-Fix solution overnight at 4°C. The cells were washed and then stained with 0.5 µg of fluorophore-conjugated anti-Foxp3-PE (eBioscience, San Diego, CA, USA) for 30 min at 4°C. After washing, the stained cells were assayed using a BD FACSCanto II flow cytometer. CD4 ) were lysed in RIPA buffer supplemented with a proteinase inhibitor cocktail (Sigma), and a total of 30 µg of protein from each group of extracts was loaded and separated on Tris-glycine SDS-PAGE gels. The following targets were probed using antibodies: IL-12p35, Ebi3, STAT1, pSTAT1, STAT3, pSTAT3, STAT4, pSTAT4, STAT5, pSTAT5, STAT6, pSTAT6, SOCS1 and β-actin (Abcam, Cambridge, UK). ECL Prime Western Blotting Detection Reagents (GE Healthcare, Piscataway, NJ, USA) and scanning densitometry (GS-710 imaging) were used to detect the signals and acquire the images. All data were obtained from three independent experiments.
Heart transplantation and treatment of recipient animals BALB/c recipient mice were transfused with 0.1 ml of PBS only (negative control), 1.0×10 5 mDCs, or 1.0×10
5 IL-35/Ebi3-mDCs (derived from BALB/c bone marrow) via an intravenous injection into the penile vein after general anaesthesia. At 24 h after transfusion, the BALB/c recipient mice underwent a fully vascularised heterotopic heart transplantation of a C57BL/6 heart using microsurgical techniques [28] . The other BALB/c recipient mice underwent heart transplantation after receiving an oral administration of 1 mg/kg of tacrolimus (positive control). The graft function was assessed daily post-operatively by palpation for evidence of contraction. Rejection was defined as the complete cessation of the heartbeat and confirmed by direct visualisation and histological examination of the graft.
Histological studies of harvested grafts
The cardiac allografts were removed from BALB/c recipient mice that were transfused with PBS, mDCs, or IL-35/Ebi3-mDCs 14 days after heart transplantation and were examined histologically and immunohistochemically. Histologic and immunohistochemical staining were performed as previously described [29] . The haematoxylin and eosin staining was assessed by grading according to the 2005 classification of the International Society for Heart and Lung Transplantation [30] to detect acute cellular rejection as follows: Grade 0, no rejection; Grade 1 (mild), interstitial and/or perivascular infiltrate with up to 1 focus of myocyte damage; Grade 2 (moderate), 2 or more foci of infiltrate with associated myocyte damage; and Grade 3 (severe), diffuse infiltrate with multifocal myocyte damage with or without oedema, haemorrhage, and/or vasculitis. Five microscopic fields were examined in each section under a microscope at an original magnification of 40×. For the immunohistochemical staining, the sections were fixed, preincubated in Block Ace and incubated with anti-Foxp3 (Abcam, Cambridge, UK), followed by an incubation with alkaline phosphatase-conjugated anti-rabbit Ig for anti-Foxp3 and Vector Blue (resulting in a blue colour). The sections were then incubated with a rabbit anti-mouse type IV collagen polyclonal antibody (LB1403; Cosmo Bio, Tokyo), peroxidase-conjugated anti-rabbit Ig and diaminobenzidine (resulting in a brown colour).
Statistical analysis
The results are expressed as the means ± SDs. Statistical significance was determined by performing unpaired t-tests or analysis of variance (ANOVA) using GraphPad Prism software. The cardiac allograft survival in the groups of mice was compared using Mann-Whitney U testing. P-values < 0.05 were considered statistically significant.
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Results
IL-35 expression was up-regulated during LPS-induced DC maturation
Previous studies have demonstrated that IL-35 was mainly secreted by Tregs or tolDCs [31, 32] . However, the expression and regulation of IL-35 on DCs remain to be clarified. In this study, LPS, TNF-α, IFN-γ and IL-1 were used to evaluate the IL-35 production by DCs in response to Toll-like receptor stimulation. The IL-35 expression level was markedly higher after LPS, TNF-α, IFN-γ and IL-1 stimulation than that observed for the imDCs group, and expression was highest with LPS treatment (Fig. 1A) . To further evaluate the expression of IL-35 following LPS stimulation, we activated DCs with LPS for different durations and found that the expression of IL-35 was time-dependent up to 4 h following LPS stimulation and reached a peak at 4 h (Fig. 1B ) compared with the control group treated with PBS. To determine whether other IL-12 family cytokines were affected by LPS, we detected the expression levels of IL-12, IL-23 and IL-27 in the cell supernatants and found that all cytokines were significantly increased in mDCs (Fig. 1C) . LPS-treated DCs exhibited upregulation of IL-12p35 and Ebi3 transcripts at much higher levels than those in untreated DCs (Fig. 1D) . IL-12p35 and Ebi3 protein levels were detected via Western blotting and were significantly increased after LPS treatment (Fig. 1E) . These results suggested that IL-35 was highly increased in DCs after LPS stimulation.
IL-35 suppressed DC maturation and promoted Treg generation
To determine whether IL-35 regulates DC maturation and function, the expression patterns of maturation-specific proteins in DCs were determined. After 24 h of stimulation + antibodies or CD4 + and IL-17A + or CD4 + and IFN-γ + antibodies. T cells were detected using flow cytometry to analyse the regulatory T cell (Treg) (D), Th17 (E) and Th1 (F) subtypes. The data shown are derived from three independent experiments and are expressed as means ± SD. *P<0.05, **P<0.01, ***P<0.001, NS denotes not significant.
Cellular
and MHC-II on DCs was hampered. Thus, IL-35 could functionally inhibit LPS-triggered DC maturation. ImDCs can preserve the production of immunoregulatory cytokines while maintaining a lower production of inflammatory cytokines. Following IL-35 activation, the DCs exhibited a strong production of IL-10 and TGF-β, whereas the secretion of IL-12, IL-23 and IFN-γ was decreased (Fig. 2B) .
To ascertain the allostimulatory capabilities of the IL-35-treated DCs, IL-35/Ebi3 or IL-35-neutralising antibody-triggered DCs were co-cultured with allogenic CD3 + T lymphocytes, and then, T cell proliferation was analysed. The results show that the proliferation of T cells was not induced by IL-35/Ebi3-treated DCs. Furthermore, the co-stimulatory capabilities of DCs after stimulation with IL-35/Ebi3 were decreased (Fig. 2C) (Fig. 2F) . Thus, IL-35 treatment caused DCs to remain immature, which then affected the balance between Treg and Th17 cells.
IL-35 could activate the STAT family to regulate DC maturation
STATs are classic transcription factors that directly engage DNA regulatory elements and thereby control the transcription of associated genes [33] . STATs have been found to intrinsically regulate DC function and importantly participate in DC maturation and the production of inflammation cytokines. Insight into one possible mechanism has been provided by an analysis of signalling via the receptor for IL-35 [34] . IL-35 signalling via STAT1 and STAT4 drive the inhibitory programme in T cells [35, 36] . We investigated whether IL-35 also affects DCs via the STAT1 and STAT4 pathways. As shown in Fig. 3 , the expression of phosphorylated STAT signalling pathway proteins in differentially treated DCs was analysed by Western blotting. We found that the expression levels of phosphorylated STAT1, STAT3 and STAT4 were significantly higher in IL-35/Ebi3-treated DCs than those in the other groups, but changes in the expression of phosphorylated STAT5 and STAT6 were not significant. Thus, IL-35 might activate the STAT1, STAT3 and STAT4 pathways to perform its biological function in DCs.
The secretion of IL-35 in DCs was regulated by let-7i via targeting SOCS1
In our previous study, we found that let-7i expression was up-regulated and could regulate the secretion of inflammatory cytokines by DCs [24] . To determine whether the expression of IL-35 was also regulated by let-7i in DCs, we transfected DCs with let-7i mimic or inhibitor and compared the effects with those produced by an NC-mimic or NC-inhibitor following stimulation with LPS. Expectedly, the transfection with the let-7i mimic resulted in the overexpression of let-7i, whereas the let-7i inhibitor suppressed the expression of let-7i in the DCs as determined by qRT-PCR. IL-35 expression was significantly higher in the let-7i inhibitor-treated DCs than in the other groups (Fig. 4A) , and the IL-35 level peaked at the 150 nmol/L concentration of the let-7i inhibitor (Fig. 4B ). According to a qRT-PCR analysis of mRNA expression, the expression levels of IL-12p35 and Ebi3 were also substantially higher in the DCs treated with the let-7i inhibitor (Fig. 4C) . We also detected the secretion levels of IL-4, IL-10, IL-12, IL-23, TGF-β and IFN-γ in the DCs transfected with the let-7i mimic or inhibitor. The transfection of DCs with the let-7i inhibitor promoted secretion of the anti-inflammatory cytokines IL-10 and TGF-β and had an inverse effect on the secretion of the pro-inflammatory cytokines IL-12 and IFN-γ (Fig. 4D) SOCS1 is a negative regulator and plays an essential role in suppressing systemic autoimmunity mediated by DCs [37, 38] . The silencing of SOCS1 enhances antigen presentation by DCs and antigen-specific anti-tumour immunity [38] . SOCS1 functions as an attenuator of antigen presentation for the control of self-tolerance through restricted pro-inflammatory cytokine signalling, such as IL-12 signalling, in mature DCs [39] . In our previous study, we investigated whether let-7i targets SOCS1 and concluded that the let7i-mediated regulation of SOCS1 protein expression was regulated by post-transcriptional effects [24] . Our qRT-PCR and Western blot results were consistent with those obtained in previous studies, which showed that the down-regulation of let-7i causes an increase in SOCS1 expression (Fig. 5A-B) . To investigate possible molecular restrictions in DCs affecting 1×10 7 ) were lysed in RIPA buffer supplemented with a proteinase inhibitor cocktail, and a total of 30 μg of protein from each group extract was loaded and separated on Tris-glycine SDS-PAGE gels. Western blotting was performed using the indicated primary antibodies, and β-actin was included as a loading control. The prefix "p" indicates phosphorylation. The blots are representative of three independent experiments. ***P<0.001.
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Cellular Physiology and Biochemistry the secretion of IL-35 in response to the down-regulation of let-7i, we tested the effect of silencing SOCS1 in DCs on the expression of IL-35. The mRNA (Fig. 5C ) and protein ( Fig.  5D ) levels of IL-12p35 and Ebi3 and the production (Fig. 5E ) of IL-35 in the supernatant all decreased. The down-regulation of let-7i observed after SOCS1 silencing did not promote DC secretion of a higher level of IL-35. This finding confirmed that let-7i might target SOCS1 to regulate the expression of IL-35 in DCs.
Transfusion of IL-35/Ebi3-treated DCs generated Tregs and prolonged cardiac allograft survival
BALB/c recipient mice transfused with PBS and mDCs rejected C57BL/6 grafts (median survival times [MSTs]: 6 days, 7 days, Fig. 6A ), whereas those transfused with IL-35/Ebi3-mDCs had significantly prolonged allograft survival (MST: 21 days). The allograft survival was slightly prolonged (MST: 11 days) in the BALB/c recipient mice that were treated with tacrolimus (1 mg/kg/day) for 7 days. The histological examinations of the cardiac allografts obtained 14 days after transplantation showed the infiltration of inflammatory cells but significantly preserved structures with a few myocardial injuries in the transplant recipients 
receiving IL-35/Ebi3-mDCs, whereas allografts from the PBS recipients showed severe myocyte damage and oedema, which were characteristic of the acute rejection process (Fig.  6B) . In each HE-stained section, a significant difference was observed by grading using a semiquantitative scale. IL-35/Ebi3-mDCs could prolong allograft survival and resulted in less histological damage.
The immunohistochemical results showed that the cardiac allografts from recipients transfused with IL-35/Ebi3-mDCs exhibited a high frequency of Foxp3 + cell infiltration (Fig.  6D) and expression of the anti-inflammatory cytokine IL-10 in the blood serum (Fig. 6E) . Then, we examined the CD4 
Foxp3
+ Tregs was significantly higher in the spleens of recipients transfused with IL-35/Ebi3-mDCs (Fig. 6C ) than in recipients transfused with PBS and mDCs. This finding was further supported by the observation that IL-35, as an inhibitory cytokine, induced DC immunosuppressive activities, suggesting that the IL-35-induced DCdriven suppressor response is meaningful in vivo. were transfected with a let-7i mimic, inhibitor or a negative control for 24 h and then treated with lipopolysaccharide (LPS), and the expression levels of suppressor of cytokine signalling 1(SOCS1) mRNA (A) and protein (B) were detected by qRT-PCR and Western blotting, respectively. The data are expressed as the means ± SDs of n = 3 samples pooled from three independent experiments. The cells were transfected with SOCS1 short interfering (si)RNA (60 nM) for 24 h before transfection with the let-7i inhibitor, treated overnight with LPS on Day 7 and then harvested. IL12p35 and Ebi3 mRNA (C) and protein (D) expression levels were determined, and IL-35 expression levels were detected via ELISA (E). The abbreviation "NC" indicates negative control compared to let-7i. The data are expressed as the means ± SDs. "NS" denotes not significant. *P<0.05, **P<0.01, ***P<0.001. IL-35, which is an inhibitory cytokine produced by thymus-derived natural regulatory T cells, is the most recently identified member of the IL-12 family. The cytokine IL-35 has attracted increasing attention as a key regulator of immunity and immunological tolerance. Recent studies indicate that IL-35 also regulates the effector functions of plasma cells and monocyte-derived DCs [10] . Although IL-35 appears to be essential to the maintenance of immune tolerance and represents a promising candidate for immunotherapy, its functionality and tolerogenic potential have been poorly investigated [4] . Immature or induced tolDCs play an essential role in the maintenance of peripheral tolerance [4] . TolDCs are generated ex vivo by culturing precursors with culture medium containing GM-CSF (mainly at a low dose) and eventually with IL-4, IL-10, or TGF-b or drugs such as vitamin-D3 (VitD3), rapamycin, tacrolimus, dexamethasone or mitomycin C [21, 40] . TolDCs are characterised by low levels of MHC-II and co-stimulatory markers, reduced secretion of pro-inflammatory cytokines, and high expression of tolerogenic molecules, such as IL-10 and TGF-β [41] . In this study, we observed consistent down-regulation of MHC-II and co-stimulatory markers following treatment of DCs with IL-35/Ebi3. In addition, IL-35 promoted the secretion of antiinflammatory cytokines, such as IL-10 and TGF-β, and decreased the secretion of IL-12 and IFN-γ in DCs. Our results demonstrated that IL-35-induced DCs tend to become immature and exhibit immune suppression functions, potentially providing a new mechanism for the regulation of DC immunity.
Figure 5
T cell-based approaches for treating inflammatory conditions, such as allergies, autoimmune diseases and graft-versus-host responses, have great potential and notable limitations [23, 42] . The therapeutic potential of human T cells is limited by their polyclonal specificity, poorly defined markers for enrichment and low proliferative capacity, which limits ex vivo population expansion. TolDCs have the capacity to induce tolerance in the peripheral tissue via the expansion or induction of several subtypes of regulatory lymphocytes, which are mainly classical induced Tregs. VitD3-treated DCs prevent T cell priming and induce the apoptosis of effector T cells. TolDCs can also induce naïve and memory T cell apoptosis [21] . Exogenous IL-35 has been shown to promote the development of Tregs, but these cells do not express Foxp3, IL-10 or TGF-β [23] . Exogenous IL-35 also has no effect on the proliferation of Th17 cells [43] . In this study, DCs treated with IL-35 potently inhibited T cell proliferation, and we also observed that IL-35-treated mDCs, but not IL-35 or mDCs alone, induced an increase in the proportion of CD4
+ Tregs and significantly suppressed increases in the Th17 cell population. Therefore, the treatment of DCs with IL-35 can further regulate T cell proliferation and function. In the context of IL-35-mediated propagation of immune tolerance, IL-35-conditioned DCs might exert a similar function on Tregs. These findings provide further insight into the ability of IL-35 to induce immature DCs, indirectly affecting T cell proliferation and expanding the Foxp3 + Treg population in vitro. Therapeutic strategies using cell products that are composed of immunoregulatory cell populations are being tested [44] . Pluripotent mesenchymal stem cells have been postulated to have immunosuppressive properties. Tan and colleagues demonstrated that autologous MSC infusion as an induction agent for living-donor kidney transplantation increased Treg generation [44, 45] . DCs with tolerogenic properties have been explored extensively in small animal models, and a meta-analysis demonstrated their potency in prolonging allograft Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry survival in multiple transplantation models [21] . For human injection, the feasibility of generating ex vivo DCs with tolerogenic properties has now been proven. The main challenge in bringing tolDCs into the clinic is the requirement of preserving their tolerogenic properties upon transfusion into the patient. However, there are two major concerns regarding the use of tolDCs in transplantation: inflammatory mediators and immunosuppressive drugs. Organ transplantation induces inflammation in the graft microenvironment that can gradually lead to tolDC maturation, and treatment with immunosuppressive drugs can affect the ability of tolDCs to induce tolerance. In this study, we transfused IL-35/Ebi3-mDCs into BALB/c heart transplant recipient mice. The mice transfused with IL-35/Ebi3-mDCs exhibited significantly prolonged allograft survival. Allograft survival was slightly prolonged in BALB/c recipients that were treated with mDCs, which can be partially attributed to the systemic delivery of IL-35/Ebi3-mDCs but not the transfer of mDCs. The IL-35-induced immature DC phenotype contributes to the Treg infiltration of cardiac allografts. IL-35 treatment of imDCs and then stimulation with LPS induces a DC hypotype that displays tolerogenic features, remains stable and is able to prolong organ graft survival. Thus, DC transfer, along with the delivery or overexpression of IL-35, may represent a potential preventive and therapeutic tool for the regulation of allograft rejection [4] . Considering the particular tolerance mechanisms employed by IL-35, its combination with other tolerogenic molecules, such as TGF-β or IL-10, might potentiate immunosuppressive effects in therapeutic settings. Unlike other diseases or conditions, transplantation involves allorecognition between two parts, the graft and the host. Autologous tolerogenic DCs may be more effective than donor tolerogenic DCs for transplantation, and the safety and efficiency of DCs have been discussed. Using donor bone marrow DCs (stimulated with low doses of GM-CSF) in a rat heart transplant model, DePaz et al. showed that tolDC therapy was able to increase rat cardiac allograft survival [46] . However, a later study using donor tolDCs or apoptotic bodies from donor tolDCs showed that tolerance was mediated by the presentation of donor peptides (from donor cells or apoptotic bodies) by recipient DCs, which inhibits CD4 + T cell activation and favours Treg expansion [22, 47] . Both therapies have been shown to be partially efficient, but on the other hand, the risk of sensitisation (including the development of alloantibodies) remains. Therefore, the use of autologous tolDCs appears to be a better alternative, at least in terms of safety, because it avoids the risk of sensitisation. In this study, autologous DCs treated with IL-35/Ebi3 displayed an immature phenotype and, upon injection the day before transplantation, were able to prolong cardiac allograft survival. We also demonstrated that rats receiving heart allografts and treated with autologous DCs transfected with let-7i achieved remarkable prolonged survival of cardiac allografts and generated Tregs [29] . These combined results demonstrated that autologous tolDCs are even more efficient than donor tolDCs. Finally, results confirming the efficacy and safety of autologous tolDCs in humans in transplantation will be evaluated in the coming years.
Conclusion
Overexpression of IL-35 regulated DC maturation and function and subsequently affected the balance between Tregs and Th17 cells. The transfusion of IL-35-transfected DCs induced the generation of Tregs in mice and prolonged cardiac allograft survival. In conclusion, our data demonstrated that IL-35 can induce DC immune tolerance and that IL-35-overexpressing DCs might be a promising approach for regulating immune tolerance and immunological disorders.
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